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Background: The anticancer and immunomodulatory activity of mung bean sprouts (MBS) and the underlying
mechanisms against human cervical and hepatocarcinoma cancer cells were explored.
Methods: MBS cytotoxicity and MBS-induced anticancer cytokines, TNF-α and IFN-β from cancer cells, and
immunological cytokines, IL-4, IFN-γ, and IL-10 from peripheral mononuclear cells (PMNC) were assessed by MTS and
ELISA assays. Apoptotic cells were investigated by flow cytometry. The expression level of apoptotic genes (Bax, BCL-2,
Capsases 7–9) and cell cycle regulatory genes (cyclin D, E, and A) and tumor suppressor proteins (p27, p21, and p53) was
assessed by real-time qPCR in the cancer cells treated with extract IC50.
Results: The cytotoxicity on normal human cells was significantly different from HeLa and HepG2 cells, 163.97 ± 5.73,
13.3 ± 0.89, and 14.04 ± 1.5 mg/ml, respectively. The selectivity index (SI) was 12.44 ± 0.83 for HeLa and 11.94 ± 1.2 for
HepG2 cells. Increased levels of TNF-α and IFN-β were observed in the treated HeLa and HepG2 culture supernatants
when compared with untreated cells. MBS extract was shown to be an immunopolarizing agent by inducing IFNγ and
inhibiting IL-4 production by PBMC; this leads to triggering of CMI and cellular cytotoxicity. The extract induced
apoptosis, in a dose and time dependent manner, in treated HeLa and HepG2, but not in untreated, cells (P < 0.05). The
treatment significantly induced cell cycle arrest in G0/G1 in HeLa cells. The percentage of cells in G0/G1 phase of the
treated HeLa cells increased from 62.87 ± 2.1%, in untreated cells, to 80.48 ± 2.97%. Interestingly, MBS IC50 induced the
expression of apoptosis and tumor suppressor related genes in both HeLa and HepG2 cells. MBS extract succeeded in
inducing cdk-inhibitors, p21, p53, and p27 in HeLa cells while it induced only p53 in HepG2 cells (P < 0.05). This is a clue
for the cell type- specific interaction of the studied extract. These proteins inhibit the cyclin-cdk complexes apart from
the presence of some other components that might stimulate some cyclins such as cyclin E, A, and D.
Conclusion: MBS extract was shown to be a potent anticancer agent granting new prospects of anticancer therapy
using natural products.Background
More attention has recently been given to the role of
plant-derived compounds as promising nutraceuticals
for controlling various disorders such as cardiovascular,
neurological, neoplastic and immunological diseases [1].* Correspondence: ahmsah73@yahoo.com; fatimah_upm_fst@yahoo.com
†Equal contributors
2Institute of Bioscience, Universiti Putra Malaysia, 43400 UPM Serdang,
Selangor Darul Ehsan, Malaysia
3Department of Microbiology, College of Medicine, Al-Nahrain University,
Baghdad, Iraq
Full list of author information is available at the end of the article
© 2012 Hafidh et al.; licensee BioMed Central
Commons Attribution License (http://creativec
reproduction in any medium, provided the orThe phytochemical compounds are found to be integral
components of human diet. They are commonly present
as constituents of flowering plants, particularly of food
plants [2].
Studies verified that phytochemicals are able to alter
the likelihood of carcinogenesis in every stage of cancer
process in a way reducing the risk but usually in a favor-
able direction [3]. Interestingly, the main activity of
these compounds depends on the fact that the exposure
of human cells to a wide variety of chemoprotective
compounds confers resistance against a broad set of car-
cinogens [4]. Much information exists nowadays on theLtd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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have concentrated on the direct and indirect actions of
phytochemicals on tumor cells, and have found a variety
of anticancer effects such as cell growth [5], kinase activ-
ity inhibition [6], apoptosis induction [7], and suppres-
sion of the secretion of matrix metalloproteinases, and
tumor invasive behavior [8]. Furthermore, some studies
reported the impairment of in vivo angiogenesis by diet-
ary phytochemicals [9]. Therefore, the discovery of new
anticancer agents from plant-derived substances is con-
sidered to be a highly promising approach in order to
enrich the pharmaceutical field with effective drugs of
lower side effects.
Besides, plants produce a vast number of natural pro-
ducts which have antimicrobial and immunomodulating
potential as defense mechanisms for adapting to various
environmental insults [10]. Many natural compounds
have shown a significant ability to regulate immune
responses [11]. Some of these phytochemicals with
immunomodulating effects are isoflavonoids, indoles,
phytosterols, polysaccharides, sesquiterpenes, alkaloids,
glucans, tannins, a variety of vitamins and trace minerals
that function as antioxidants and co-enzymes, and many
other phytochemical substances [12].
It is clear that human immune response is a highly com-
plex and extraordinarily sophisticated system involving
both innate and adaptive mechanisms [13]. Immunomodu-
lating activity refers to biological or pharmacological effects
of compounds on humoral or cellular aspects of the im-
mune response. In other words, immunomodulation is the
process of modifying an immune response in a positive or
negative manner by administration of a drug or a com-
pound [11]. Although the field of study of immune enhan-
cing compounds is relatively not new [14], natural
products from plants represent a rich and promising
source of novel molecules with immunomodulating prop-
erties that may augment a disease recovery alone or to-
gether with commercially known drugs.
For the first time in the field, the current study
investigated the in vitro selective cytotoxic and immu-
nomodulatory effects of mung bean sprout (Vigna
radiata L.) methanol crude extracts on human cancer
and peripheral mononuclear cells (PMNC), respect-
ively. The rationale behind testing the anticancer and
immunomodulatory effects of MBS extract is that first,
MBS has not been assessed as anticancer or as immu-
nomodulatory agent before, second, MBS is a germin-
ating plant which usually possesses very high levels of
antioxidants that are well known to act as potent antic-
ancer and immunomodulatory agents. More in depth,
this study explored thoroughly the underlying mechan-
isms of the newly discovered findings in the current
study, namely, the novel anticancer and immunomodu-
latory effects of mung bean sprout (Vigna radiata L.)methanol extract by using cytological and molecular
assays for assessing and measuring anticancer cyto-
kines, cell cycle phases, percentage of apoptotic cells,
expression level of cell cycle genes, tumor suppressor
genes and apoptosis genes in MBS treated and un-
treated cancer cells. Moreover, PBMC-secreted cyto-
kines, in response MBS extract exposure, were
measured as an indicator for the immunomodulatory
effect of MBS. Therefore, the ultimate goal of the
current study is to find a natural anticancer product able to
inhibit the proliferation of human cancer cell lines with
high selectivity index, safe usage, and effective anticancer
activity. This study has been patented in Malaysian intellec-
tual property (MyIPO) under Malaysian patent application
number PI2011001617 on 12th April 2011 (http://www.
rmc.upm.edu.my/upmip/index.php?content=getfaculty&ipi
d=683&ipdetailid=671&projectlead=151&cluster=3&fac=8)
and the current patented research has been considered for
commercialization by University Putra Malaysia.
Methods
Ethical approach
The current study was conducted in compliance with
Helsinki Declaration for ethical approaches of conduct-
ing scientific research. This study was approved by the
ethical committee of University Putra Malaysia in Kuala
Lumpur.
Preparation of the MBS extract
Fresh mung bean sprouts (MBS), devoid of any preserva-
tive antimicrobials was purchased from local markets in
the State of Selangor, Malaysia. The growth of mung beans
and the germination of the sprouts were done in Selangor
State. The mung bean sprouts were left to dry in dark area
for three days at room temperature 23-25°C. After the dry-
ness of sprouts, they were ground to powder. The ground
powder was extracted 1:10 wt/v with 2.4 M HCl acidified
methanol (Merck, Darmstadt, Germany) to extract all, free
and conjugated, components of phenolic compounds [15];
the ground powder was then soaked in dark area for three
days at room temperature. The supernatant was collected
after filtration and the fresh solvent was added to the plant
material. The extraction procedure was repeated twice and
the collected extracts were evaporated to dryness under
vacuum at 40°C by using rotary evaporator. To remove the
effect of the acidity from the crude extract, the crude ex-
tract of MBS was neutralized to exclude any pH-related ef-
fect. The pH for MBS extract was neutral ranging from 6.8
to 7.0. The dried extracts were stored at −18°C in a desic-
cant until further use.
Preparation of stock extract
The stock extract for MBS was prepared by redissolving
the MBS extract powder in dimethyl sulfoxide (DMSO)
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is usually non toxic to cell culture [16]. Moreover, this
concentration was tested in the current study and was
found to be non toxic to HeLa and HepG2 cells. The vi-
tality of cells incubated with DMSO (0.1%) was tested by
MTT assay for different time intervals and was com-
pared with that of control cells We found that both
tested HeLa and HepG2 cells kept their vitality and
freshness with DMSO concentration of 0.1% when com-
pared to control cells with fresh medium [data not
shown]. Afterwards, the dissolved suspension was centri-
fuged at 134 g for 10 min and filtrated by 0.22 μm Milli-
pore filters (Nalgene, UK). The stock was stored at −20°C
until it further use. The concentration of the stock extract
was determined as required.
Cancer cells propagation and cryopreservation
Two human cancer cell lines, namely, cervix adenocarcin-
oma cells (HeLa; ATCC CCL-2) and hepatocellular carce-
noma (HepG2; ATCC HB-8065), were used to evaluate the
cytotoxic effects of MBS extract. Cells were propagated as
monolayer under humidified 5% CO2 atmosphere at 37°C
in Roswell park memorial institute-1640 (RPMI-1640) cul-
ture medium w/L-glutamine (biowest, Florida, USA) sup-
plemented with 10% fetal bovine serum (FBS) (Sigma,
Germany), 50 U/ml penicillin-streptomycin (biowest, Flor-
ida, USA), and 2.5 μg/ml amphotericin B (biowest, Florida,
USA). Part of the cells was cryopreserved for future work
in liquid nitrogen (−196°C) after suspending in RPMI-1640
cryospreserved medium supplemented with 10% FBS, 20%
DMSO, 50 U/ml penicillin-streptomycin, and 2.5 μg/ml
amphotericin B.
Isolation of human peripheral blood mononuclear cells
(PBMC)
Human PBMC were isolated by density gradient centrifu-
gation technique from heparinized whole blood. Thirty
milliliters of fresh heparinized blood sample isolated from
normal donor and diluted in phosphate buffer saline (PBS),
(CALBIOCHEM, Darmstadt, Germany) were gently laid
over 15 ml of Ficoll Hypaque (GE Healthcare Bio-sciences
AB, Sweden) and were spun at 500 g for 20 min at 25°C.
PBMC were collected from the interface of spun blood
samples and were washed three times with PBS by centri-
fugation at 500 g for 10 min at 4°C. The supernatant was
discarded and the cells were suspended in RPMI-1640 cul-
ture medium. Trypan blue solution 0.4% (Sigma, Germany)
was used to count the cells into an appropriate concentra-
tion and the viability of cells was checked; the required
range of cells’ viability is 95-99%.
MTS tetrazolium assay
In order to determine the viable cells in proliferation or
cytotoxicity assays, the MTS colorimetric method (theCell Titer 96® Aqueous One Solution Cell Proliferation
Assay, Promega, USA) was used. MTS [3-(4,5-
dimethylthiazol-2-yl)-5-(3-carboxymethoxyphenyl)-2(4-sul-
fophenyl)-2H-tetrazolium] is reduced by dehydrogenase
enzymes in metabolically active cells producing soluble
colored formazan in tissue culture medium. The quantity
of formazan products, measured at 490 nm absorbance
after 4h incubation time, is directly proportional to the
number of living cells in the culture [17]. The absorbance
was measured using a 96-well plate ELISA reader (Sunrise
Basic Tecan, Grödig, Austria).
Proliferation and cytotoxicity assays for PBMC
Purified mononuclear cells, 2 × 105 cell/well, were cul-
tured in quadruplicate in 96-well U-bottom tissue cul-
ture plates (Orange Scientific, Europe) with 2-fold serial
dilutions of each extract in RPMI-1640 culture medium
to a final volume of 200 μl/well. The MBS extract con-
centrations ranged from 300 to 9.37 mg/ml. The nega-
tive control wells, in quadruplicates, contained PBMC in
RPMI-1640 culture medium (200 μl/well). The positive
control wells, in quadruplicates, contained PBMC with
Concavalin A (Con A), (10 μg/ml), a T-cell specific mito-
gen (Sigma, Germany), at a final volume of 200 μl/well.
The plates were used to assess the cytotoxicity or the
stimulatory effect of the extracts on PBMC proliferation.
Cultures were incubated in humidified 5% CO2 atmos-
phere for 72h at 37°C. After 72h, 20 μl of MTS solution
with 100 μl of RPMI-1640 culture medium were added
to each well. The plates were incubated for four hours at
the same conditions. Later, the absorbance was mea-
sured at 490 nm (reference 690 nm) using a 96-well
plate ELISA reader. Each experiment was repeated for
three times with four wells per dilution in each run.
The extract effect to stimulate PBMC proliferation was
calculated using the following formula:
Proliferation % ¼ ODt=ODcð Þ–1½   100
Where (ODt) indicates the optical density of the tested
extract and (ODc) indicates the optical density of the
negative control [18].
On the other hand, the data of the extract cytotoxicity
against PBMC was calculated using the following for-
mula:
Cytotoxicity % ¼ 1– ODt=ODcð Þ½   100
Where (ODt) indicates the optical density of the tested
extract and (ODc) indicates the optical density of the
negative control. Accordingly, the concentration of 50%
inhibition (CC50) was the concentration that achieved
50% cytotoxicity against PBMC [19].
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Cytotoxicity assay was performed according to the estab-
lished method of Mena-Rejon et al. (2009), where 1 ×k 105
cell/well viable HeLa and HepG2 cells were grown in
RPMI-1640 culture medium in 96-well flat-bottom tissue
culture plates (Orange Scientific, Europe). The plates were
incubated in humidified 5% CO2 for 24h at 37°C. When
cells reached > 80% confluence, the medium was replaced
with 200 μl/well of 2-fold serial dilutions of MBS extract
from 164 to 10.25 mg/ml prepared in RPMI-1640 mainten-
ance medium (with 2% FBS). The concentration of MBS
extract was 328 mg/ml. The negative control wells con-
tained DMSO (0.1%) in RPMI-1640 maintenance medium
with final volume of 200 μl/well. All the plates were incu-
bated in humidified 5% CO2 for 24h at 37°C. Later, all the
wells’ contents were removed and replaced with 200 μl/well
of RPMI-1640 maintenance medium. The plates were re-
incubated for 48 h at the same conditions. Afterwards, 20
μl of MTS solution with 100 μl of RPMI-1640 culture
medium were added to each well. The plates were incu-
bated for four hours in the same conditions. The absorb-
ance was measured at 490 nm (reference 690 nm) using a
96-well plate ELISA reader. Each experiment was repeated
for three times with four wells per dilution in each run [20].
The concentration of the extract that killed 50% of the
cells (IC50) was calculated using the following formula:
Cytotoxicity % ¼ 1– ODt=ODcð Þ½   100
Where (ODt) indicates the optical density of the tested
extract and (ODc) indicates the optical density of the
negative control. The selectivity index (SI) was the ratio
of CC50 (cytotoxicity on PBMC) to the IC50 (cytotox-
icity on human cancer cells), [19].
Cytokine production by PBMC
In order to evaluate the immunomodulatory effect of MBS
extract, the cytokine level produced from PBMC after
treatment with MBS extract was investigated. PBMC at
2×105 cell/well were cultured, in triplicates, in 96-well U-
bottom tissue culture plates with 2-fold serial dilutions of
the extract in RPMI-1640 culture medium to a final vol-
ume of 200 μl/well. The extract concentrations ranged
from 100 to 3.12 mg/ml. The negative control wells, in tri-
plicates, contained 200 μl/well of PBMC in RPMI-1640
culture medium. After 24 h of incubation at 37°C in hu-
midified 5% CO2 atmosphere, the plates were centrifuged
at 300 g for 10 min. The supernatant was collected and
centrifuged at 1000 g for 10 min to be ready to determine
the cytokine level produced into the medium [21].
Cytokine production by human cancer cell lines
The level of anticancer cytokines, IFN-β and TNF-α,
was investigated in treated and untreated HeLa andHepG2 cells. HeLa and HepG2 cells at 1 × 105 cell/well
were grown in RPMI-1640 culture medium in 96-well
flat-bottom tissue culture plates in a humidified 5% CO2
atmosphere for 24 h at 37°C. Later, serial 2-fold dilutions
of MBS 10 to 0.31 mg/ml prepared in RPMI-1640 main-
tenance medium were added to the cells, in triplicates,
to a final volume of 200 μl/well. The MBS extract stock
concentration was 20 mg/ml. The negative control wells,
in triplicates, contained cells with RPMI-1640 mainten-
ance medium only with final volume of 200 μl/well. The
plates were incubated for 48h at the same conditions.
Afterwards the supernatants from all the wells were
removed and centrifuged at 1000 g for 10min to be
ready for the ELISA technique [22].
Measuerment of cytokines produced by PBMC and cancer
cells
The levels of immunomodulatory cytokines, IL-2, IL-4
and IFN-γ, in the PBMC culture supernatant with and
without extract treatment, and the levels of anticancer
cytokines, IFN-β and TNF-α, in the supernatant of cul-
tured treated and non-treated cancer cells, were mea-
sured. The procedures pursued were according to the
manufacturers’ instructions of each kit. For IL-2 and IL-
4, the used kit was human enzyme immunometric assay
(EIA) kits (Cayman, USA), for IFN-γ, a human interferon
gamma ELISA kit (abcam, USA) was used, and for antic-
ancer cytokines, human IFN-β ELISA (abcam, USA) and
TNF-α human enzyme immunometric assay (EIA) kits
(Cayman, USA) were used.
Each microtiter plate was already coated with mono-
clonal antibodies specific for the corresponding cytokine.
The standards of IL-2 and IL-4 were reconstituted in the
same matrix of the samples, namely RPMI-1640 medium
plus each 2-fold serial dilution of the extract; this step is
needed to match the color effect of unpurified samples
that might persist even after the subsequent washing
steps. Accordingly, a standard curve was made for each
dilution of the extracts used. The IL-2 or IL-4 standards
were prepared as 2-fold serial dilutions ranging from
250 to 3.9 pg/ml in eight tubes of 15 ml capacity (Or-
ange Scientific, Europe); the eighth tube contained zero
concentration of IL-2 or IL-4 standard.
For IFN-γ, standards were freshly prepared by reconsti-
tuting in the standard diluents buffer to give a stock con-
centration of 400 pg/ml. Two hundred microliter of this
stock was added, in triplicates, to the already coated micro-
titer plates provided by the kit. Each plate was coated with
monoclonal IFN-γ specific antibodies. From stock wells,
serial 2-fold dilutions of IFN-γ standard were prepared by
diluting the standard in a matrix similar to that of the sam-
ples which is RPMI-1640 culture medium plus each dilu-
tion of the extracts used. This step is needed to match the
color effect of unpurified samples that might persist even
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ard curve was made for each dilution of the extracts used.
IFN-γ standard concentrations ranged from 400 to 12.5
pg/ml; and the last standard contained zero concentration
of IFN-γ standard in the sample matrix.
For immunomodulatory cytokines, IL-2, IL-4, IFN-γ, and
anticancer cytokines, IFN-β and TNF-α, one hundred μl of
standards, samples, and conjugates were all assayed as tri-
plicates. For IL-2 and IL-4, the absorbance was measured
at 412 nm (reference 690 nm) using a 96-well plate ELISA
reader. The assay was repeated for three times for each
sample. The concentrations of samples’ IL-2 and IL-4 were
determined by extrapolating their OD values with that of
the generated standard curves. For IFN-γ, the absorbance
was measured at 450 nm (reference 620 nm) by ELISA
reader. The sample concentrations were determined by ex-
trapolating OD values to IFN-γ concentrations using the
generated linear standard curves (the average absorbance
on the vertical axis versus the corresponding IFN-γ stand-
ard concentration on the horizontal axis). One hundred μl
of sample, conjugates and substrate-chromogen were used
according to the guidelines of the kits manufacturer. Later,
the absorbance was measured at 412 nm (reference 690
nm) and at 450 nm (reference 620 nm) using a 96-well
plate ELISA reader for TNF-α and IFN-β plates, respect-
ively. The assay was repeated for three times for each sam-
ple. The concentrations of the cytokines were determined
by extrapolating their OD values with that of the generated
standard curves.
Analysis of apoptosis
Flow cytometry analysis for cell apoptosis
Flow cytometry can rapidly quantify and evaluate the
properties of apoptotic cells. It can give information on
the ratio of apoptotic cells, based on the cellular size or
DNA contents. It is well known that several differences
are present between apoptotic cells and normal cells.
These differences can be utilized by flow cytometric tech-
niques for apoptosis detection [23]. The cells (HeLa and
HepG2) were seeded (1 × 105 cell/well) in 6-wells tissue
culture plates and were incubated in a humidified 5%
CO2 atmosphere for 24 h at 37°C. The medium was then
replaced with RPMI-1640 maintenance medium with or
without MBS extract and was incubated for further 24 h
at the same conditions. The cell treatment was divided
into two groups. In the first group (dose-dependent
group), the effect of three 2-fold serial dilutions of the ex-
tract (concentration > IC50 > concentration) was investi-
gated regarding the level of apoptosis, if any, after a fixed
time. The concentrations of MBS extract were 26.6, 13.3,
and 6.65 mg/ml with HeLa cells and were 28.08, 14.04,
and 7.02 mg/ml with HepG2 cells. In the second group
(time-dependent group), the IC50 of MBS extract was
used to investigate the level of cells’ apoptosis as well ascell cycle arrest after different time intervals of incuba-
tion with the extract. For the first group, after 24 h, the
cells were harvested and transferred to 15 ml tubes. All
of the tubes were centrifuged at 190 g for 10 min. The
supernatants were discarded and the pellets were washed
two times by cold PBS. Later, the pellets were resus-
pended in 70% ice-cold ethanol with PBS, 1:10 v/v, and
were incubated for 2h at −20°C. Then, all the superna-
tants were aspirated after centrifugation at 500 g for
10 min. The washing step by PBS was repeated and the
supernatants were aspirated. The pellets were resus-
pended in 500 μl of DNA staining solution containing
25 μl of propidium iodide (PI) 1 mg/ml (MP Biomedicals,
LLC, IIIKrick, France), a double-stranded nucleic acid
intercalating agent, and 50 μl Ribonuclease A from bo-
vine pancrease (1 mg/ml), (Sigma, Germany) in PBS. All
the tubes were incubated on ice in dark area for 30min
[24]. The assay was measured in duplicate for each sample.
The propidium iodide fluorescence of individual nuclei
was measured using CyAn ADP apparatus (BECKMAN
COULTER, USA). The software Summit (V4.3) was used
to analyze the flow cytometry results.
For the second group of the flow cytometry analysis, the
stock extract was prepared and the same method men-
tioned earlier for the first group was used except for the
following differences: the IC50 for MBS extract with HeLa
and HepG2 cells was used to treat the cells. The IC50 of
MBS extract was 13.3 mg/ml with HeLa cells and
14.04 mg/ml with HepG2 cells. The group was subdivided
into seven treatments (8, 12, 16, 20, 24, 48 and 72 h). The
assay was measured in duplicate for each sample in the
specific time of treatment.
Detection of apoptosis- and cell cycle arrest- related genes
by real time quantitative PCR (qRT-PCR)
The current trend of research uses advanced techniques
in molecular biology to study the apoptosis- and cell
cycle arrest- related genes’ expression such as Bcl-2 fam-
ily, members of caspase family, tumor suppressor pro-
teins, and cyclins. Nowadays, by using the reverse
transcription-polymerase chain reaction (RT-PCR), the
scientists can demonstrate the level of mRNA expression
of apoptosis and cell cycle proteins even though they are
expressed only in a small cell population in tissues [25].
RNA extraction
The cells (HeLa and HepG2) were seeded (1 × 105 cell/
well) in 6-wells tissue culture plates and were incubated in
a humidified 5% CO2 atmosphere for 24 h at 37°C. The
medium was then replaced with RPMI-1640 maintenance
medium either alone or with MBS extract, in duplicates,
and the medium was incubated at the same conditions.
The IC50 for MBS extract against each type of cells was
used. The IC50 of MBS extract was 13.3 mg/ml with HeLa
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the best timing for studying the apoptosis and cell cycle ar-
rest by flow cytometry, treatment of cells with extract for
12, 16, and 20 h was conducted. At the end of 12, 16, or
20h of extract treatment, the cells were harvested and
transferred to 15 ml tubes. After centrifuging the tubes at
134 g for 5 min, the supernatants were discarded. The pel-
lets were resuspended in PBS and were washed for four
times.
It is noteworthy to mention that one of the most import-
ant steps preceding the synthesis of good quality cDNA is
the isolation of intact (undegraded) total RNA from cul-
tured cells or tissues [25]. Total RNA was isolated using
GF-1 kit (Vivantis Technologies, Malaysia). According to
the manufacturer’s protocol for RNA isolation from cell
culture, 1 × 107 cells were precipitated in 1.5 ml microtubes
(Eppendrof, Hamberg, Germany) at 1000 × g for 5 min.
The cell pellets were resuspended in 700 μl of lyses buffer
(Buffer TR) with vigorous mixing by vortexing. This buffer
is specially formulated to inactivate cellular RNases to-
gether with cell lysis. Later, the lysed cells were transferred
to homogenization columns assembled in a collection
tubes. The columns were centrifuged at 10.000 × g for
2 min. The flow-though was saved and equal volume of
80% ethanol (700 μl) was added. The lysed cells were mixed
thoroughly by pipetting and were transferred into RNA
binding columns assembled in collection tubes. RNA bind-
ing columns were centrifuged at 10.000 × g for 1 min and
the flow-though was discarded. The columns were washed
by adding 500 μl of washing buffer and were centrifuged at
14.000 × g for 1 min. The flow-though was discarded and
all of the DNA fragments were removed by DNase I treat-
ment. Seventy microlitter of DNase I Digestion Mix were
added to RNA binding columns and were incubated at
room temperature for 15 min. DNase I Digestion Mix was
composed of DNase I (7 μl), digestion buffer (56 μl), and di-
gestion enhancer (7 μl). Then, 500 μl of inhibitor removal
buffer were added to the columns which were centrifuged
at 14.000 × g for 1 min. The columns were washed with
500 μl washing buffer for two times with centrifugation at
10.000 × g for 1 min for each run. Further centrifugation at
10.000 × g for 1 min was done to remove any traces of buf-
fer. Total RNA was collected by placing the columns into
new 1.5 ml microtubes with 60 μl RNase-free water
addition and standing for 1 min. The microtubes were cen-
trifuged at 10.000 × g for 1 min. RNA quality and quantity
were determined by Life Science UV/Vis Spectrophotom-
eter, DU Series 700 (BECKMAN COULTER, USA).The iso-
lated RNA was stored at −80°C and was ready for use in
downstream application, namely, qRT-PCR.
Real time quantitative RT-PCR
One microgram of the isolated RNA from each sample
was reverse-transcribed by iScript™ cDNA Synthesis Kit(BIO-RAD, Hercules, Canada). According to the manufac-
turer’s protocol, 4 μl of 5 × iScript reaction mix were mixed
with 1 μl iScript reverse transcriptase and 15 μl of RNA
template in 1.5 ml microtubes to give final volume of 20 μl
per reaction. The complete reaction mix was incubated for
5 min at 25°C then for 30 min at 42°C using Thermo Bath,
ALB64 (FINEPCR, Seoul, Korea). The incubation temperature
was increased to 85°C for 5 min. Finally, cDNA was stored at
−80°C for qRT-PCR reaction.
Real-time quantitative PCR reaction was conducted using
SsoFast™ EvaGreen® Supermix (BIO-RAD, Hercules,
Canada). Depending on the manufacturer’s protocol, 10 μl
of 1x SsoFast EvaGreen supermix were mixed with 7 μl
RNase/DNase free water. One microlitter of forward primer
(500 nM) and 1 μl of reverse primer (500 nM) were added
to the previous mix (Table 1). Finally, 1 μl of cDNA template
corresponding to 50 ng of total RNA was added. The PCR
reaction (20 μl) was run for 40 cycles using CFX96™ Real-
Time System (BIO-RAD, Hercules, Canada). Cycling condi-
tions were 95°C for 3 min, 95°C for 10 sec, 55-61°C for
30 sec, and 72°C for 20 sec. PCR reaction for cDNA
templates from untreated HeLa and HepG2 cells were
used as negative controls. The PCR reaction was run in
triplicate for each target gene. PCR reaction mix without
cDNA template was used to detect any contamination.
At the end of the amplification, measurement of Eva
Green fluorescence was done continuously with the con-
duction of the melting curve analysis by slow heating at
0.5°Cs-1 increments from 70 to 95°C, with continuous
fluorescence collection. Accordingly, a melting curve was
generated at the end of the PCR amplification for moni-
toring the specificity of PCR reaction. Melting curve ana-
lysis of the negative first derivative was pursued. Beta-
actin was used as a housekeeping gene (reference gene)
to normalize the mRNA expression of target genes. Be-
cause PCR efficiency may vary among different primers,
the calculation of PCR primers’ efficiency is essential for
obtaining accurate measurements of the relative expres-
sion of the mRNA of target genes [26]. For this reason, a
standard curve was created by diluting template cDNA of
each single primer used in this study. The cDNA tem-
plate for each primer was serially diluted (10-1 to 10-7);
each dilution serves as a standard. In this reaction, cDNA
template was used from samples with high expression to
the target of interest. The amplification efficiency can be
obtained by analyzing the slope of the log-linear portion
of the standard curve. When the logarithm of the initial
template concentration is plotted on the x axis and the
threshold cycle (Ct) is plotted on the y axis, PCR effi-
ciency is calculated according to the following equation
[26]:
PCR efficiency ¼ 101=slope–1
Table 1 Primers used in Real-Time quantitative PCR analysis (Vivantis Technologies, Malaysia)
Forward primer Reverse primer
Bax CAC CAG CTC TGA GCA GAT GCG AGG CGG TGA GCA CTC
BCL-2 TAC CTG AAC CGG CAC CTG GCC GTA CAG TTC CAC AAA GG
Caspase 7 GTC TCA CCT ATC CTG CCC TCA TTC TTC TTC TGC CTC ACT GTC
Caspase 8 GAA AAG CAA ACC TCG GGG ATA C CCA AGT GTG TTC CAT TCC TGT C
Caspase 9 CCA GAG ATT CGC AAA CCA GAG G GAG CAC CGA CAT CAC CAA ATC C
Cyclin D AGA CCT GCG CGC CCT CGG TG GTA GTA GGA CAG GAA GTT GTT C
Cyclin E CTC CAG GAA GAG GAA GGC AA TCG ATT TTG GCC ATT TCT TCA
Cyclin A GTC ACC ACA TAC TAT GGA CAT G AAG TTT TCC TCT CAG CAC TGA C
p21 GTG ATT GCG ATG CGC TCA TG TCT CTT GCA GAA GAC CAA TC
p27 GTC TAA CGG GAG CCC TAG CC CTA ACC CCG TCT GGC TGT CC
p53 TGT GGA GTA TTT GGA TGA CA GAA CAT GAG TTT TTT ATG GC
β-actin (reference gene) TCA CCC TGA AGT ACC CCA TC CCA TCT CTT GCT GCA AGT CC
Note: all primers are listed 5’-3’.
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used to relatively quantify the target genes according to
the following equation [27]:
Ratio ¼ Etarget
 ΔCt target controlsampleð Þ
= Erefð ÞΔCtRef control–sampleð Þ
In which (E): represents the amount of fold change per
cycle per gene. Ref: represents the reference gene. Tar-
get: represents the target gene.
It has been well known that the ratio of Bax to Bcl-2
determines, in part, the susceptibility of cells to death
signals [28]. Therefore, the Bax to Bcl-2 ratio was calcu-
lated using the following equation:
Bax=Bcl 2 ratio
¼ mean PCR efficiency for Bax and Bcl 2ð Þ CtBcl2–CtBaxð Þ
Data analysis
All the data in the current study are shown as mean±2SE.
The selectivity index (SI) was determined by using the ratio
of CC50 to IC50. The data analysis was conducted by using
SPSS software version (12.0.0.2). The effect of the tested
extract on the inhibition of cell growth was evaluated by
using 95% confidence intervals. IC50 and CC50 values
were calculated using linear regression index equations.
The statistically different effects of the extract on the
ability of PBMC, HeLa and HepG2 cells to synthesize
selected cytokines were compared with the controlTable 2 The cytotoxic effect of MBS extract on cancer cell line
Extract Cancer cell line aCC50 mg/ml bIC50
MBS HeLa 163.97 ± 5.73 13.3 ±
HepG2 163.97 ± 5.73 14.04 ±
Note: aThe results of CC50 (on peripheral blood mononuclear cells) are shown as m
cSelectivity index represents the ratio of CC50/IC50. The results are shown as meangroups using the Student’s t-test. For flow cytomteric
analysis, R2 fraction represented sub-G apoptotic cells;
moreover, the percentage of cells at different cell cycle
phases was calculated from the total cells minus apop-
totic cells. For quantitative real time PCR, the up- or
down- regulation of mRNA expression of selected genes
was measured as expression fold changes in term of
mean±2SD. The significance of up- or down- regulation
of the normalized mRNA expression of selected genes
was determined by comparing the mean ± 2SD of any
up- or down- regulation with the mean ± 2SD of con-
trol (untreated cells), equal to 1 ± 2SD. P values less
than 0.05 were considered significant.Results
Cytotoxicity on human cancer cells
The results of the current study revealed that the cyto-
toxic effects of MBS extract on normal human cells
(PBMC) was significantly different (P < 0.05) from that
on human cancer cells (Table 2). The cytotoxic effect of
MBS extract on PBMC, expressed as CC50, was 163.97
mg/ml while its IC50 on HeLa cells was 13.3 mg/ml and
on HepG2 cells was 14.04 mg/ml. These findings
revealed that MBS extract required high concentrations
to be cytotoxic on normal human cells (Figure 1) while
only low concentrations were enough to give the same
effect on human cancer cells (Figure 2). These resultss
mg/ml P value P < 0.05 cSI
0.89 6.54539E-06 Significant 12.44 ± 0.83
1.5 7.25478E-06 Significant 11.94 ± 1.2
ean±2SE. bThe results of IC50 (on cancer cell lines) are shown as mean ± 2SE.
± 2SE.
Figure 1 The percentage of PBMC death after treatment with
2-fold serial dilutions of MBS extracts in term of mean ± 2SE
(confidence interval CI 95%).
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as cytotoxic agents (Figure 3).
The cytotoxicity of MBS extract on PBMC, HeLa and
HepG2 cells was dose dependent. In other words, theFigure 2 The percentage of A) HeLa and B) HepG2 cells death after tr
mean ± 2SE (confidence interval CI 95%.cytotoxicity of MBS extract decreased with higher dilu-
tions, lower concentrations, of the extract. The signifi-
cant differences of MBS cytotoxicity were supported by
the results of the selectivity index (SI) which is the ratio
of the highest concentration that causes 50% death to
normal cells (CC50) to the lowest concentration that
causes 50% death to cancer cells (IC50). The SI values of
MBS extract demonstrated effective SI values on HeLa
cells, 12.44, and HepG2 cells, 11.94 (Table 2). The cyto-
toxic effect of MBS extract showed no significant differ-
ence between HeLa and HepG2 cells.
Non-specific immune response by PBMC
The results of the proliferation assay of PBMC treated
with MBS extract were not significant. According to the
formula of the proliferative %, the data of the prolifera-
tion % for PBMC were the same for that of the cytotox-
icity % but in negative values (Figure 1). The results
showed that MBS extract has no proliferative effect on
PBMC when compared to the mitogenic effect of Con A
(proliferative % = 63.89 ± 4.7). Instead, MBS extract
showed a cytotoxic effect on these cells but this cytotoxic
effect is of far less impact than that on the cancer cells.A
B
eatment with 2-fold serial dilutions of MBS extract in term of
a b
c
Figure 3 Figures demonstrate the level of the produced cytokines, in comparison with negative control (neg-ctl), in culture
supernatant of peripheral blood lymphocyte cell after treatment with mung bean sprout extract (MBS): a) IL-2, b) IFN-γ and c) IL-4.
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tions less than that of the CC50 (Figure 3) to avoid any mi-
nute cytotoxic effect by the extract and to allow cytokines
production, if any. The cytokine production assay showed
that there was no significant difference (P > 0.05) in the
level of IL-2 production between the treated PBMC and
the control group, the untreated PBMC. Thus, PBMC trea-
ted with MBS extract did not produce IL-2 in a significant
amount when compared with untreated PBMC (Table 3).
However, there was a significant difference (P < 0.05) in
the level of IFN-γ in PBMC culture supernatants of MBS-
treated and MBS-untreated cells.. It was shown that IFN-γTable 3 The level of IL-2 produced by PBMC after










P value P < 0.05
100 90.6 ± 11.64 76.26 ± 12.3 0.41 Non-significant
50 88.47 ± 14.6 0.53
25 86.42 ± 8.47 0.5
12.5 86.11 ± 9.33 0.53
6.25 84.75 ± 10.18 0.6
3.12 83.63 ± 12.85 0.68
Note: *All the results are shown as mean ± 2SE.
IL-2 level of each extract concentration was compared with that of the
negative control (PBMC without extract).level in PBMC treated with MBS extract was high in cells
treated with high concentrations of the extract; on the
other hand, the level of IFN-γ decreased in dose dependent
manner with decreasing concentrations of MBS extract in-
dicating a stimulatory effect of MBS extract on the synthe-
sis of IFN-γ by PBMC (Table 4). Moreover, the results
indicated the dose dependent nature of IFN-γ synthesis by
PBMC in response to MBS extract treatment.
On the other hand, the level of Th2 cytokine, IL-4, in
culture supernatants of PBMC treated with MBS extract
was much lower than in untreated cells (P < 0.05). These
findings demonstrated a significant decrease of IL-4Table 4 The level of IFN-γ produced by PBMC after










P value P < 0.05
100 288.63 ± 13.65 84.38 ± 11.5 < 0.0001 Significant
50 238.57 ± 20.5 < 0.0001 Significant
25 204.62 ± 12.64 < 0.0001 Non-significant
12.5 133.85 ± 10.53 0.006 Non-significant
6.25 102.49 ± 9.69 0.24 Non-significant
3.12 87.92 ± 11.22 0.83 Non-significant
Note: *All the results are shown as mean ± 2SE.
IFN-γ level of each extract concentration was compared with that of the
negative control (PBMC without extract).
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centrations of MBS extracts used in the treatment of
PMBC. This reflects clearly an inhibitory effect of MBS
extract on the production of IL-4 cytokine (Table 5).
Specific immune response by human cancer cells
The human cancer cell lines were treated with MBS ex-
tract concentrations less than the IC50 for each extract.
These concentrations allowed the detection of the antic-
ancer cytokines production in the culture supernatants
of HeLa and HepG2 cells (Figure 4). The IFN-β levels in
culture supernatants of HeLa and HepG2 treated with
MBS extract showed significant and dose-dependent in-
crease (P < 0.05) when compared to that of untreated
cells (Tables 6 and 7). Accordingly, MBS extract revealed
a clear stimulatory effect on the synthesis of IFN-β by
both HeLa and HepG2 cells. Similarly, TNF-α levels
showed a remarkable increase in the culture superna-
tants of HeLa and HepG2 cells treated with MBS extract
when compared to that of untreated cells. Clearly, the
MBS-driven increase of TNF-α levels was also in a dose
dependent manner (Tables 8 and 9).
MBS extract induced apoptosis and cell cycle arrest in
human cancer cells
The flow cytometric analysis showed possibility of MBS ex-
tract to induce apoptosis in the treated cells in comparison
to untreated cells (Figures 5 and 6). By testing the apop-
tosis for fixed time interval, 24 h, and by using different
doses of MBS extract, the percentage of the apoptotic cells
were directly correlated with the concentration of MBS ex-
tract. MBS extract induced apoptosis, in a dose dependent
manner, in treated HeLa and HepG2 cells while no
observed apoptosis was found in untreated cells (P < 0.05).
The IC50 of MBS extract induced apoptosis in 56.6 and
55.4% of HeLa and HepG2 cells, respectively, after 24 h of
treatment (Figure 7).Table 5 The level of IL-4 produced by PBMC after










P value P < 0.05
100 21.63 ± 6.8 71.52 ± 9.94 0.001 Significant
50 37.5 ± 7.11 0.015 Significant
25 41.86 ± 10.4 0.022 Significant
12.5 58.9 ± 9.48 0.37 Non-significant
6.25 62.6 ± 12.56 0.62 Non-significant
3.12 68.19 ± 7.2 0.9 Non-significant
Note: *All the results are shown as mean ± 2SE.
IL-4 level of each extract concentration was compared with that of the
negative control (PBMC without extract).By testing apoptosis at different time intervals, the flow
cytometric analysis of HeLa and HepG2 cells treated with
the IC50 of MBS extract showed that the extract provoked
significant apoptosis (P < 0.05) in the treated HeLa and
HepG2 cells in a time dependent manner when compared
with untreated cells (Figure 8). There were no significant
differences (P > 0.05) in the percentage of HeLa and
HepG2 cells in different cell cycle phases when treated
with MBS IC50 for different times (Figures 9A and 10A).
However, MBS IC50 induced cell cycle arrest in G0/G1
phase in the treated HeLa, but not HepG2 when com-
pared to untreated cells. The mean percentage of HeLa
cells, treated with MBS extract for different times, in
G0/G1 phase was higher than that in untreated cells
(Figure 9B). The treatment with MBS IC50 increased
the percentage of HeLa cells in G0/G1 phase from
62.87 ± 2.1%, in untreated cells, to 80.48 ± 2.97%. Alter-
natively, MBS IC50 did not increase significantly the
percentage of HepG2 cells in G0/G1 phase from 60.83
± 3.6, in untreated cells, to 65.30 ± 3.25% (Figure 10B).
The apoptosis- and cell cycle- related genes in human
cancer cells treated with MBS extract
The results disclosed that 12, 16, and 20 h were the best
times to study the expression level of the apoptosis- and
cell cycle- related genes using real-time quantitative
PCR. The other treatments of 8, 24, 48, and 72 h were
ignored because they either gave very low or very high
percentage of apoptotic cells. Studying the apoptosis-
and cell cycle- related genes cannot be covered well dur-
ing very early phase of extracts’ treatment during which
not all apoptosis genes might be upregulated or downre-
gulated; alike, during very late phase of apoptosis, most
cells already died which renders measuring the expres-
sion of selected genes erroneous. A single peak at the
expected melting temperature of PCR product, melting
temperature (Tm) 76-87°C, was observed while no sig-
nificant premature peaks were found indicating that pri-
mer dimers were minimal and providing further
evidence on the specific detection of the target mRNA
genes (Figure 11). The PCR efficiency of the primers
used was greater than 90% and the correlation coeffi-
cients were greater than 0.99.
MBS IC50 showed remarkable influence on the expres-
sion of the apoptosis-related genes in a positive and nega-
tive manner on both HeLa and HepG2 cells (Figures 12
and 13). MBS IC50 upregulated Bax gene expression in
HeLa and HepG2 cells after 12, 16, and 20 h (P < 0.05).
Bax upregulation at 16 h was not significantly different
from that at 12 and 20 h (P > 0.05). Incubating HeLa
and HepG2 cells with MBS IC50 did not show any ef-
fect on Bcl-2 gene expression after all the tested times
of incubation (P > 0.05). MBS IC50 upregulated Caspase
7 gene expression after 12, 16, and 20 h of treatment of
a b
c d
Figure 4 Figures demonstrate the level of the produced cytokines, in comparison with negative control (neg-ctl), in culture
supernatant of HeLa cell (a and b) and HepG2 cells (c and d) after treatment with MBS extract.
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Caspase 7 gene in the treated HepG2 cells only after 16 h
(P < 0.05) with no significant difference from 12 h upregu-
lation (P > 0.05). The expression of Caspase 8 gene in the
treated HeLa cells was upregulated after 12, 16, and 20 h
of treatment (P < 0.05) with no significant differences
among the expressions of all of them (P > 0.05). At the
same time, MBS IC50 upregulated Caspase 8 and 9
genes’ expressions in HepG2 cells only after 16h (P <
0.05) with no significant differences in their expressions
from 12 h treatment (P > 0.05). On the contrary, MBSTable 6 The level of IFN-β produced by cancer cells, HeLa,











P value P < 0.05
10 142.85±13.18 19.54±8.23 <0.0001 Significant
5 116.83±11.52 <0.0001 Significant
2.5 94.8±10.32 <0.0001 Significant
1.25 51.67±11.47 0.04 Significant
0.625 31.67±11.3 0.4 Non-significant
0.31 27.31±8.47 0.73 Non-significant
Note: *All the results are shown as mean ± 2SE.
IFN-β level of each extract concentration was compared with that of the
negative control (HeLa without extract).IC50 upregulated Caspase 9 gene expression in the treated
HeLa cells after 12h (P < 0.05) with significant differences
(P < 0.05) from that after 16 and 20h treatments.
The ratio of Bax to Bcl-2 proteins influences the apop-
totic rate of cells; therefore, Bax/Bcl-2 ratio was calcu-
lated in treated and untreated HeLa and HepG2 cells
(Table 10). The ratio of Bax/Bcl-2 in the treated HeLa
and HepG2 cells after 12, 16, and 20h with MBS IC50
was higher than in the untreated cells (P < 0.05).
Because flow cytometric analysis showed cell cycle ar-
rest by MBS extracts at G0/G1 phase, the regulatoryTable 7 The level of IFN-β produced by cancer cells,











P value P < 0.05
10 147.38±16.38 21.56±8.48 <0.0001 Significant
5 102.67±18.43 0.002 Significant
2.5 89.21±11.42 0.0001 Significant
1.25 71.68±12.73 0.006 Significant
0.625 37.5±9.58 0.23 Non-significant
0.31 30.17±7.34 0.6 Non-significant
Note: *All the results are shown as mean ± 2SE.
IFN-β level of each extract concentration was compared with that of the
negative control (HepG2 without extract).
Table 8 The level of TNF-α produced by cancer cells,











P value P < 0.05
10 121.72 ± 16.83 42.74 ± 8.26 0.001 Significant
5 104.36 ± 15.28 0.004 Significant
2.5 89.42 ± 12.16 0.007 Significant
1.25 55.69 ± 8.28 0.28 Non-significant
0.625 41.3 ± 7.39 0.89 Non-significant
0.31 41.13 ± 6.71 0.87 Non-significant
Note: *All the results are shown as mean ± 2SE.
TNF-α level of each extract concentration was compared with that of the
negative control (HeLa without extract).
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cyclin D, E, and A were studied. These cyclins are re-
sponsible for the activation of cyclin-dependent kinases
(cdk) in G1 and S phases of the cell cycle of HeLa and
HepG2 cells. Moreover, the mRNA expression of the
proteins responsible for the inhibition of cyclin-cdk ac-
tive complexes of the G1 and S phases of HeLa and
HepG2 cells exposed to the IC50 of MBS extracts were
studied as well, namely tumor suppressor proteins p27,
p21, and p53 (Figure 4.24 and Figure 4.25).
The current findings of real-time quantitative PCR were
congruous with that of flow cytometry. In addition, the
results of real time PCR granted valuable details on some
aspects and mechanisms that underlie the cell cycle arrest
ability of MBS extract. For MBS extract effect on HeLa
cells, it was found that the expression of both cyclin D
and E, cyclins of G0/G1 phase, was downregulated after
12, 16, and 20h exposure of HeLa cells to MBS extractTable 9 The level of TNF-α produced by cancer cells,











P value P < 0.05
10 118.47±18.3 37.21±9.98 0.002 Significant
5 95.28±12.89 0.003 Significant
2.5 70.14±14.22 0.08 Non-significant
1.25 43.85±12.63 0.68 Non-significant
0.625 31.56±8.91 0.67 Non-significant
0.31 33.16±6.38 0.74 Non-significant
Note: *All the results are shown as mean ± 2SE.
TNF-α level of each extract concentration was compared with that of the
negative control (HepG2 without extract).with no significant differences (P > 0.05) while the expres-
sion of cyclin A, cyclin of late G1 and S phase, was not
affected by MBS extract (P > 0.05). However, the cdk-
inhibitory protein, p27 was significantly upregulated after
16 h (P < 0.05) while its upregulation after 12 and 20h was
not significant (P > 0.05) indicating that p27 peak of upre-
gulation was around 16h. For p21 and p53, both of them
were largely upregulated, especially p21, after 12 and 16 h
(P < 0.05) but not after 20 h (P > 0.05). The upregulation
of p21 reached 128 folds of expression after 12 h and
above 512 folds of expression after 16 h while the upregu-
lation of p53 reached 16 folds after 12 h and more than 32
after 16 h. Both p53 and p21 are expressed together for
the inhibition of cyclin-cdk complexes and peaked after
16 h of cells exposure to MBS extract indicating a clear
inhibiting role of MBS extract for the cell cycle at G0/G1
through cdk-inhibitory proteins rather than affecting
much the expression level of cyclins themselves.
The effect of MBS extract on HepG2 cells was some-
how different from its effect on HeLa cells. MBS extract
did not show, via both flow cytometry and real time
PCR, a remarkable inhibitory effect on the cell cycle of
HepG2 cells. The mRNA expression level of cyclin D
and A was not affected by MBS extract (P > 0.05) while
cyclin E was upregulated after 12 h (P < 0.05). Moreover,
the expression of p27 and p21 proteins did not reach the
significant level of upregulation (P > 0.05) indicating that
MBS extract has little inhibitory effect on the cell cycle
of HepG2 cells. Nevertheless, p53 was the only protein
shown to be significantly upregulated after 12 and 20 h
(P < 0.05) and borderline upregulation (P = 0.048) after
16h. However, it is not well understood why p53 was
upregulated while other tumor suppressor proteins were
not. Collectively, the current results of the effect of MBS
extract on HepG2 are in harmony with flow cytometry
results. Both assays revealed weak inhibitory effect of
MBS extract on HepG2, but not HeLa, cells indicating a
cell-specific activity of MBS extract on the cell cycle of
different types of cells. The sole upregulation of p53 by
MBS extract explains some aspects of the remarkable
apoptotic activity of MBS extract towards HepG2 cells.
Discussion
The cytotoxic effects of MBS extract was investigated on
two of the most important types of cancer in Asian coun-
tries. Depending on recent studies, hepatocellular carcin-
oma, a liver cancer, is considered to be one of the most
common cancers worldwide with an extremely poor prog-
nosis. Moreover, it ranks as the second leading cause of
cancer-related deaths in China and many Asian regions
[29]. On the other hand, cervical cancer continues to be
the commonest cause of death among women in develop-
ing countries. In addition, it is the second most frequent





Figure 5 DNA content frequency histograms representing HeLa cells after 24 h from (a) untreated cultures (b) cultures treated with
MBS extract concentration <IC50 (c) cultures treated with MBS extract IC50 (d) cultures treated with MBS extract concentration >IC50.
The treatment affected the cell cycle distribution and induce apoptosis. The cells were stained with PI. Fluorescence of the PI-stained cells was
measured using CyAn ADP appartus and Summit (V4.3) software. The software program provides the estimate of percentage of cells with
fractional DNA content (apoptotic cells: R2) and cells in G0/G1 (R3), S (R4), and G2/M (R5) phases of the cycle. Total cell number (R1).






Figure 6 DNA content frequency histograms representing HepG2 cells after 24 h from (a) untreated cultures (b) cultures treated with
MBS extract concentration <IC50 (c) cultures treated with MBS extract IC50 (d) cultures treated with MBS extract concentration >IC50.
The treatment affected the cell cycle distribution and induce apoptosis. The cells were stained with PI. Fluorescence of the PI-stained cells was
measured using CyAn ADP appartus and Summit (V4.3) software. The software program provide the estimate of percentage of cells with
fractional DNA content (apoptotic cells: R2) and cells in G0/G1 (R3), S (R4), and G2/M (R5) phases of the cycle. Total cell number (R1).
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AB
Figure 7 A graph of flow cytometric analysis shows the percentage of apoptotic cells after treatment with MBS extract for 24 h in
comparison with untreated cells (Negative control). The extract’s concentrations represent 2-fold serial dilutions (concentration > IC50 >
concentration). A) Apoptotic % of HeLa cells. B) Apoptotic % HepG2 cells. The increase in the percentage of the apoptotic cells was dose
dependent.
Hafidh et al. BMC Complementary and Alternative Medicine 2012, 12:208 Page 15 of 24
http://www.biomedcentral.com/1472-6882/12/208The findings of the current study revealed effective
cytotoxic effects on HeLa and HepG2 cells by MBS ex-
tract. No previous studies have investigated the cytotoxic
effect of MBS extract. Interestingly, in the current study,
MBS extract showed selective cytotoxic effects against
both HeLa and HepG2 cells with SI values of 12.44 and
11.94, respectively. Taken into account the SI biological
efficacy, or SI, ≥ 10 is considered not due to non-specific
cytotoxicity, the SI values of MBS extract reflect remark-
able selectivity. There is a need to find new chemical
agents able to differentiate between normal and cancer-
ous cells. This is a necessary criterion to selectively kill
cancer cells and this such selective natural proidcts have
become highly needed [31]. It has been proven that ger-
mination of the mung bean causes a rise in the total
content of the antioxidant components like phenolic
compounds, α-tocopherol and vitamin C [32]. The ab-
sence of significant differences in MBS cytotoxic effects
on HeLa and HepG2 cells may highlight the common
cytotoxic mechanisms that are possibly used by theextract to seize the cell growth of both cell lines. One of
the possible mechanisms responsible for the cytotoxic
effect of MBS extract is the great possibility of flavonoids
and phenolics in reducing alkylperoxyl radical (ROO•)
content which has a role in radical-mediated pathogen-
esis such as carcinogenesis. It was found that the scaven-
gers of alkylperoxyl radical (ROO•) may play an
important role in cancer prevention [33]. Another pos-
sible mechanism that may explain the results of this
study is the synergistic effect of phenolic compounds
and α-tocopherol. It was observed that phenolic com-
pounds indirectly increase the (ROO•)-scavenging cap-
acity in vivo by increasing the level of α-tocopherol [33].
It is known that α-tocopherol, one of vitamin E family
members, has a potent antioxidant activity [34]. In
addition, many studies proved the efficacy of α-tocoph-
erol as antithrombotic, anticoagulant, neuroprotective,
antiproliferative, immunomodulatory, cell membrane-
stabilizing, and antiviral [35-38]. Thus, the clear cyto-
toxic effect of MBS extract may be related to the efficacy
AB
Figure 8 A graph of flow cytometric analysis showes the percentage of apoptotic cells after treatment with MBS extract comparison
with untreated cells. The percentage of apoptotic cells increased with the time of treatment by extract IC50. A) Apoptotic % of HeLa cells.
B) Apoptotic % of HepG2 cells. The increase in the percentage of the apoptotic cells was time dependent.
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phenolic compounds. Besides, the presence of anticarci-
nogenic substances, such as vitamin C, [40] in the ger-
minated mung bean sprouts may enhance the cytotoxic
effect of MBS extract.
MBS extract was shown to be a good inducer for both
anticancer cytokines, i.e., TNF-α and IFN-β in culture
supernatants of HeLa and HepG2 cells. There was a sig-
nificant increase in their levels in MBS-treated cells when
compared to untreated cells. The increase was dose
dependent which reflected the capability of MBS extract
as an inducer to the production of these two essential
anticancer cytokines. Both TNF-α and IFN-β are import-
ant cytokines to regulate cell growth and death [41]. A
recent study found that TNF-α and IFN-β are major in-
ducible cytokines that function to counteract cellular
transformation in a synergistic action [42]. Accordingly,
the current study clarified that MBS extract induced the
production of TNF-α and IFN-β from human cancer
cells, and this led to the inhibition of the growth of these
cells and this might lead to the death of treated human
cancer cells. The cytokines synthesized by cancer cellsare released to culture medium and then bind to their
receptors on the cell surface of cancer cells, leading to
cell growth arrest and apoptosis via an autocrine pathway
[22]. The anticancer activity of IFN-β has been well
recognized [43], whereas TNF-α plays a paradoxical role
in carcinogenesis [44]. The ability of MBS extract to in-
duce the production of anticancer cytokines was in
agreement with some recent findings. Several studies
demonstrated that α-tocopherol is considered as a potent
antitumor agent which increases apoptosis and decreases
proliferation in tumor cells [45,46]. Similarly, vitamin C
proved to have cytotoxic action on human cancer cells
and induce apoptosis [47]. And, it was found that vitamin
C is capable to induce TNF-α production in vivo [48].
Thus, the cytotoxic effect of MBS extract could be partly
explained by the induction of anticancer cytokines which
in turn induces cell death; moreover, all these actions
may be induced by the two important components of
MBS extract, i.e., α-tocopherol and vitamin C.
Besides inducing anticancer cytokines, there was a need
to explore the pro-apoptotoic effect of MBS extract on
cancer cells. The flow cytometry analysis was done to
AB
Figure 9 A) Cell cycle arrest of HeLa cells treated by MBS extract IC50 at different time intervals. B) The mean ± 2SE of the percentage of
cells at G0/G1, S, and G2/M phases of the cell cylce of HeLa cells treated with MBS extract for different times in comparison with that of
untreated cells.
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the treated HeLa and HepG2 cells. The results revealed
that MBS extract induced apoptosis in the treated cells in a
dose and time dependent manner with significant differ-
ences from untreated cells. The cell cycle arrest and the in-
duction of apoptosis in cancer cells have become major
indicators of anticancer effects [49]. Moreover, the antitu-
mor effects could be attributed to altered biochemical
mechanisms, including inhibitions of proliferation, induc-
tion of cell cycle arrest at various cell cycle checkpoints,
and enhanced apoptosis [50]. The current study revealed
that treated HeLa and HepG2 cells with the IC50 of MBS
extract induced cell cycle arrest significantly in G0/G1
phase in HeLa but not in HepG2 cells. The mean percent-
age of HeLa cells, treated with MBS extract for different
times, in G0/G1 phase was higher than in untreated cells
(Figure 9). The treatment with MBS IC50 increased the
percentage of HeLa cells in G0/G1 phase from 62.87 ±
2.1%, in untreated cells, to 80.48 ± 2.97%. Alternatively,
MBS IC50 did not increase significantly the percentage ofHepG2 cells in G0/G1 phase from 60.83 ± 3.6, in untreated
cells, to 65.30 ± 3.25% (Figure 10). The results of this study
were in agreement with other previous studies which
found that flavonoids, phenolic acids, and other antioxi-
dants inhibit the cancer cell cycle progression, cell prolif-
eration and tumor growth. In addition, they can prevent
tumor metastasis by inducing cell-cycle arrest and apop-
tosis [51,52].
Subsequently, real-time quantitative PCR was used to
confirm the deteted aoptotisis by flow cytometry and to
detect the underlying mechanism(s) used by MBS ex-
tract to induce apoptosis. To demonstrate these mech-
anism(s), the expression of several apoptosis-related
genes was investigated in the current study. Apoptosis is
a broad network of signals that act through two major
apoptotic pathways: the extrinsic death receptor pathway
(via caspase 8), which triggers the activation of a caspase
cascade, and the intrinsic mitochondrial pathway (via
caspase 9), which shifts the balance in the Bcl-2 family
towards the pro-apoptotic members and, consequently,
AB
Figure 10 A) Cell cycle arrest of HepG2 cells treated by MBS extract IC50 at different time intervals. B) The mean ± 2SE of the
percentage of cells at G0/G1, S, and G2/M phases of the cell cylce of HepG2 cells treated with MBS extract for different times in comparison with
that of untreated cells.
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and 9 are considered as initiator caspases which in turn
can activate the effector caspases, namely caspase 3 and
caspase 7, leading to dramatic morphologic changes of
apoptosis [54]. In the current study, MBS extract was
found to be a potent inducer to the extrinsic pathway of
apoptosis via caspase 8. MBS extract upregulated the
gene expression of caspase 8 after 12 h of treatment in
both HeLa and HepG2 cells. Caspase 8 upregulation
continued till 20 h in the treated HeLa cells while it con-
tinued maximally till 16 h in the treated HepG2 cells. It
has been shown that the activation of caspase 8 requires
the involvement of apoptotic ligands such as TNF-α and
Fas ligand [53]. As mentioned earlier, MBS extract sti-
mulated TNF-α production in the culture supernatants
of the treated HeLa and HepG2 cells. Thus, we propose
that TNF-α which was produced by the treated cells
might have an autocrine effect on the same producing
cells. And it activated the extrinsic apoptosis pathwayvia caspase 8 by binding to its receptors on the surface
of cancer cells.
The current results revealed that MBS extract upregu-
lated the expression of Bax gene after 12 h of treatment
and this upregulation continued till 20 h. It was stated
that cytochrome c release from mitochondria could be
controlled by Bax. And the translocation of Bax can alter
the outer mitochondrial membrane permeability, leading
to cytochrome c release from the mitochondria to the
cytosol then activation of the intrinsic apoptosis pathway
[55]. Accordingly, MBS extract promoted the intrinsic
apoptosis pathway by its ability to upregulate Bax gene.
Moreover, the results demonstrated the predominance
of Bax gene over Bcl-2 gene in all of the treated cells. It
was proven that the ratio of Bax to Bcl-2 determines, in
part, the susceptibility of cells to death signals [28]. For
that reason, Bcl-2 proteins have emerged as an attractive
target for the development of novel anticancer drugs,
and this could be one of the targets hit by MBS active
Figure 11 The melting curve analysis of the PCR products at the end of the amplification was done by measuring the Eva Green
fluorescence by slow heating at 0.5°Cs-1 increments from 70 to 95°C, with continuous fluorescence collection. Accordingly, a melting
curve was generated at the end of the PCR amplification for monitoring the specificity of PCR reaction. It was found that a single peak (single
product) at the expected melting temperature of PCR product, Tm 76-87°C, was observed while no significant premature peaks were found
indicating that primer dimers artifacts or incorrect amplification products were minimal and providing further evidence on the specific detection
of the target mRNA genes.
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effect on the level of Bcl-2 expression in the treated
HeLa and HepG2 cells with MBS extract, the Bax/Bcl-2
ratio in cells treated with MBS extract was high after
16h, for HeLa cells, and was high after 20h, for HepG2.
Hence, this ratio may explain in part the susceptibility of
the MBS-treated HeLa and HepG2 cells to apoptosis.
The upregulation of caspase 9 in HeLa and HepG2 cells
was clear after 12h of treatment with MBS extract. It is well
known that caspase 9 can be activated by caspase 8 or can
be activated independently on binding of cytochrome c re-
lease from the mitochondria [56]. We assumed that the in-
trinsic apoptosis pathway induced by MBS extract in the
treated cancer cells might be provoked via direct upregula-
tion of caspase 9 gene, via the activation of caspase 8 by the
extrinsic pathway, or via the upregulation of Bax gene. In
addition, MBS extract induced the expression of caspase 7
gene in the treated HeLa and HepG2 cells after 12h. Cas-
pase 7 can be activated by both extrinsic and intrinsic path-
ways of apoptosis. Moreover, caspase 7-dependent pathway
without caspase-3 activation is recently considered as
caspase-independent apoptosis pathway. And caspase 7 can
activate caspase 12 which results in the induction of apop-
tosis during endoplasmic reticulum stress [57]. Therefore,
the results of the current study disclosed a fact that MBS
extract might induce apoptosis by different pathways. The
reason behind these results is that we are dealing with a
curde extract with a large number of different components
that could trigger different pathways of apoptosis. Accord-
ingly, using MBS extract might have advantage orver single
active componnents in triggering two or three pathways of
apoptosis simultaneously leading to vigorous induction ofapoptosis. The induction of multi-pathway apoptosis usu-
ally leads to effective anticancer activity able to overcome
any resistance that might issue from cancer cells against
apoptotic signals or against one of the apopotitic pathways.
For this reason, finding new natural anticancer products
has increasingly become a favorable trend of treating can-
cer. In addition, the current results highlight the ability to
isolate more than one effective cytotoxic component from
MBS extract.
The regulatory proteins of cell cycle evaluated in the
current study were chosen carefully in order to give fur-
ther image on the underlying mechanisms for the
observed G0/G1 arrest as well as apoptosis found in
MBS-treated HeLa and HpeG2 cells. The studied mar-
kers were the cdk-activating proteins, namely cyclins
and cdk-inhibitors, namely CKI or tumor suppressor
proteins, such as p27, p21, and p53. Interestingly, MBS
extract succeeded in inducing all the studied cdk-inhibi-
tors, p21, p53, and p27 in HeLa cells while it induced
only p53 in HepG2 cells. This is a clue for the cell type-
specific interaction of MBS extract. This feature necessi-
tates studying the cell growth- inhibiting activity of
plants’ extracts individually on different human cancer
cell lines. The peak time for the induction of tumor sup-
pressor proteins was after 16 h. Therefore, after 20 h,
most affected cells died due to either cell cycle arrest or
apoptosis. Upon comparing the current results with
these of flow cytometry, it is obvious that both results
are in harmony. Via flow cytometry, MBS extract caused
slight and insignificant arrest in G1 phase of cell cycle of
HepG2 cells but not HeLa cells. This feature was
explained by the results of real time PCR. MBS extract
AB
Figure 12 Real-time quantitative PCR analysis illustrates the gene expression in (A) HeLa cells and (B) HepG2 cells after 12, 16, and
20 h of treatment with the IC50 of MBS extract. The gene expression was normalized with the reference gene (β-actin). The relative
quantification of the target genes, Bax, Bcl-2, Caspase 7 (Casp 7), Caspase 8 (Casp 8), and Caspase 9 (Casp 9), by the delta–delta–Ct method was
done using the software BIO-RAD CFX Manager (V 1.1.308).
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p53, and p27 in HepG2 cells while it largely induced
p21, p53, and p27 in HeLa cells.
The current findings of the cell cycle inhibitory effects
of MBS extract showed weak or absent influence on the
expression of cdk-activating cyclins. Instead, MBS ex-
tract showed remarkable induction and upsurge of cdk-
inhibitor proteins. Therefore, it is concluded that these
cdk-inhibitor proteins are the main mechanism pursued
by MBS extract to exert the G1 cell cycle arrest and ul-
timately the final fate, death of cells.
In addition, the current study revealed an interesting
finding on MBS extract; it induced synthesis of TNF-αfrom cancerous cells. TNF-α can be the central link be-
tween the extract and its remarkable ability to induce cdk-
inhibitors and/or to downregulate cyclins. TNF-α was
found to induce p21 (waf1) protein in tumor cells, and it
also induces p21 binding to CDK 2/4 and 6 complexes
resulting in the inhibition of their activities [58]. This in-
hibition drives cells to G1 arrest. In addition, p27Kip1 was
reported to induce caspase -dependent and -independent
phases of cell death through TNF-α signaling [59].
In the current study, another antitumor cytokine was
found to be secreted by tumor cells in response to MBS
extract, namely IFN-β. Like TNF-α, IFN-β is most prob-
ably linked to the apoptotic and cell cycle slowing/
Figure 13 Real-time quantitative PCR analysis illustrates the gene expression in (A) HeLa cells and (B) HepG2 cells after 12, 16, and
20 h of treatment with the IC50 of MBS extract. The gene expression was normalized with the reference gene (β-actin). The relative
quantification of the target genes, Cyclin D (CYCD), Cyclin E (CYCE), Cyclin A (CYCA), p27, p21, and p53, by the delta–delta–Ct method was done
using the software BIO-RAD CFX Manager (V 1.1.308).
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growth of tumor cells by blocking the progression of
their cell cycle via the upregulation of the cyclin-
dependent kinase inhibitor p21 (waf1), [60]. Moreover,Table 10 A table summarizes the susceptibilty of the treated
depending on the ratio between the pro-apoptotic protein (B
Extract-cells Bax/Bcl-2 untreated Bax/Bcl-2 treated 12h P value
MBS-Hela 0.31 ± 0.03 2.35 ± 0.22 0.004
MBS-HepG2 0.64 ± 0.06 2.75 ± 0.25 0.005
Note: the ratio was calculated as mean ± 2SE.
The ratio of the treated cells was calculated after 12, 16, and 20 h of treatment withTNF and IFN molecules were shown to synergistically
induce a G1 arrest associated with reduced levels of cyc-
lin D1 and cdk2, and increased expression of the cdk
inhibitors p16INK4a, p21WAF1 and p27Kip1 [61]. In aand untreated HeLa and HepG2 cells to apoptosis
ax) and the anti-apoptotic protein (Bcl-2)
Bax/Bcl-2 treated 16h P value Bax/Bcl-2 treated 20h P value
10.71 ± 2.75 0.023 2.82 ± 0.55 0.016
4.09 ± 1.01 0.027 4.22 ± 1.25 0.038
the IC50 of MBS extracts.
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omerase activity in ovarian cancer and this signaling was
found to be mediated by p21(waf1) [62]. Interestingly,
two previous studies proved the positive signaling path-
way between IFN-β and p53 and p21 proteins in indu-
cing cell cycle arrest and apoptosis [63,64].
Immunomodulatory activity of MBS extract
The reason behind studying the immunomodulatory ef-
fect of MBS extract is that MBS is rich in flavonoids
[65]. These compounds are able to stimulate CD4+ T
lymphocytes that represent the major source of the IL-2
cytokine [66]. However, this study revealed a non-
significant effect of MBS extract on IL-2 production
from human PBMC. These results were supported by
the findings of the proliferation assay which was per-
formed on the same cells treated with MBS extract. The
results showed negative effect of MBS extract on PBMC
proliferation instead of a positive effect.
Cell-mediated immune response is an important aspect
of host resistance to infection and cancer. It is thought to
be tightly regulated by balance between type 1 cytokines
(Th1) including IL-2, IFN-γ, TNF-α, and IL-12 and the
type 2 cytokines (Th2) such as IL-4, IL-6, and IL-10 [13].
Immunomodulators can be divided into main three
groups, i.e., immunostimulating, immunosuppressive, and
immunopolarizing agents, which all are useful for different
therapeutic needs [67]. MBS extract was found to lack the
immunostimulatory effect. Nevertheless, MBS extract was
shown to shift the polarization of PBMC towards type 1
(Th1) rather than type 2 (Th2); this polarization deter-
mines the prognosis of many infectious diseases. And most
importantly MBS-polarization can shift immune response
from humoral to cell-mediated immunity (CMI) where the
anti-tumor immune cytotoxicity lies. The immunomodula-
tory effect of MBS extract was evaluated by studying the
production of IFN-γ and IL-4 by PBMC cultured in vitro
with MBS extract. IFN-γ and IL-4 are key cytokines for the
development of type 1 and type 2 immune responses, re-
spectively [68]. The current study showed that MBS extract
increased reamrakably IFN-γ and decreased IL-4 levels in
the supernatant of PBMC culture when compared with un-
treated (control) cells. The increase and the decrease in
IFN-γ and IL-4 levels, respectively, were dose-dependent;
the highest increase in IFN-γ or the highest decrease in IL-
4 levels were driven by the highest concentration used of
MBS extract, 100 mg/ml. The immunopolarizing effect of
MBS extract towards Th1 immune response could be in
agreement with a previous study which found that α-toc-
opherol induces high secretion of IFN-γ in vivo [69]. The
role of IFN-γ in enhancing antitumor immunity has been
well proven by inducing CD8+ cells-based cellular cytotox-
icity and by inducing abundant production of IL-12 which
stimulates natural killer (NK) cells that act together withCD8+ cells as the main immunological cytotoxicity defense
line against tumors [70]. Moreover, ascorbic acid (vitamin
C), the other major components of MBS extract, also
induces IFN-γ production by stimulating Th1 pathway
cytokines [71,72]. In addition, the immunopolarizing effect
of MBS extract shown in this study could be supported by
a previous study which found a remarkable hepatoprotec-
tive role of mung bean aqueous extract in curing liver in-
jury during hepatotoxicity [73]. The hypothesis behind the
hepatoprotective action of mung bean aqueous extract
could be due to its ability to induce the production of IFN-
γ. Interferon gamma is produced by certain subsets of
natural killer T cells in the liver which are the primary
mediators of antitumor responses [74,75]. Accordingly, in
addition to the direct antitumor cytotoxicity and the induc-
tion of antitumor cytokines by MBS extract, the third anti-
tumor mechanism of MBS could be attributed to the
induction of IFN-γ production and immunoplorization of
immune resposne towards CMI and cellular cytotoxicity.
Conclusion
The cytotoxic effects of MBS extract were investigated
thoroughly. The current study showed significant cyto-
toxic effects exerted by MBS extract against human cer-
vical cancer cells and human hepatocarcinoma cells. The
cytotoxicity of MBS extract to HeLa and HepG2 cells
was shown to be hgihly selective. Moreover, MBS extract
was found to act as a potent inducer for apoptosis in the
treated human cancer cells via caspase-dependent, both
extrinsic and intrinsic pathways, and may be caspase-
independent pathway. MBS extract induced apoptosis
and cell cycle arrest in the treated human cancer cells
via cell-type specific interactions. Cdk-inhibitor proteins
(p21, p27, and p53) were the main mechanisms used by
MBS extract to exert G1 cell cycle arrest and ultimately
the final fate of cells, apoptosis.
In addition, MBS extract induced synthesis of TNF-α and
IFN-β from cancerous cells and this might be associated
with the apoptotic and cell cycle slowing/arresting capabil-
ity of MBS extract. Interestingly, MBS extract was shown to
be an immunopolarizing agent by inducing IFN-γ and inhi-
biting IL-4 production by PBMC. This triggers CMI and
cellular cytotoxicity which are critical defense mechanisms
against cancer, allergy, and different pathogens.
Taken together, the findings of the current study indi-
cated that MBS extract is a highly promising cytotoxic
agent by affecting either known or new targets in the antic-
ancer chemotherapy. And these anticancer activities were
thought to be driven by more than one component giving
chance for MBS extract to exert strong, multi-mechanism,
and synergistic anticancer and/or immunomodulatory
effects. As the current study is unpredecented in exploring
the anticancer activitieis and underlying mechanisms of
MBS extract, further study is needed urgently to identify
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anticancer and immonumodaltory powerful and selective
activities of MBS extract.
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